AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) –
– Updating 2026 Full Year Guidance – BRIDGEWATER, NJ, November 3, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2026.
“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT ® , and BREKIYA ® autoinjector. The Kashiv integration is proceeding well, and we are excited about the long-term growth potential in biosimilars. With the breadth and depth of opportunities across our portfolio, we remain highly confident in Amneal’s robust growth outlook,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.
Net revenue in the third quarter of 2026 was $863 million, an increase of 10% compared to $785 million in the third quarter of 2025. Affordable Medicines net revenue increased 19%, driven by biosimilars, women’s health patches, and new launches. Specialty net revenue increased 20%, driven by key branded products, including CREXONT ® , BREKIYA ® autoinjector, and UNITHROID ® . AvKARE net revenue decreased 17%, as expected, due to a non-recurring cardiovascular product launch in the prior year.
Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in the third quarter of 2026 compared to net income of $2 million in the third quarter of 2025 as higher revenue and gross profit were more than offset by non- recurring acquisition and integration costs, and higher tax provision.
Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025, reflecting higher revenue, higher gross profit, and lower operating expenses.
Diluted loss per share in the third quarter of 2026 was $(0.06) compared to diluted income per share of $0.01 for the third quarter of 2025, due to the aforementioned factors and higher share count as a result of the Kashiv acquisition. Adjusted diluted earnings per share in the third quarter of 2026 was $0.26, an increase of 53% compared to $0.17 for the third quarter of 2025.
The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information. 1
We are increasing full year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS. The Company is also updating operating cash flow guidance, reflecting working capital, including higher inventory levels in key growth areas.
Updated Guidance Prior Guidance Net revenue $3.15 billion - $3.25 $3.10 billion - $3.20 billion billion Adjusted EBITDA(1) $800 million - $815 $750 million - $780 million million Adjusted diluted $1.04 - $1.08 $0.96 - $1.06 EPS(2) Operating cash flow(3) $325 million - $375 $350 million - $400 million million Operating cash flow, $350 million - $400 $375 million - $425 excluding discrete million million items(4) Capital ~$150 million ~$150 million expenditures(5)
(1) Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.
(2) Accounts for non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.
(3) Represents cash provided by operating activities. (4) Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $40 million.
(5) Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment. Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, November 3, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 304152835. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding product launches; statements regarding our potential growth and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other 2 events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.
Such risks and uncertainties include, but are not limited to: risks related to integrating our acquisition (the “Kashiv Acquisition”) of Kashiv BioSciences, LLC (“Kashiv”) and realizing the anticipated benefits of the acquisition; our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.
Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non- GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results and facilitate an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.
These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working 3 capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as an alternative to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.
A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 157,399 $ 282,029 Restricted cash 14,174 28,842 Trade accounts receivable, 1,016,844 895,143 net Inventories 707,956 606,302 Prepaid expenses and other current 196,769 98,395 assets Related party receivables 1,876 470 Total current assets 2,095,018 1,911,181 Property, plant and 572,634 442,950 equipment, net Goodwill and intangible 2,323,728 1,158,968 assets, net Operating lease 69,760 38,832 right-of-use assets Operating lease right-of-use assets - 20,019 15,216 related party Financing lease 63,255 53,328 right-of-use assets Other assets 122,807 57,805 Total assets $ 5,267,221 $ 3,678,280 Liabilities and Stockholders’ Equity (Deficiency) Current liabilities: Accounts payable and $ 788,831 $ 761,316 accrued expenses Current portion of liabilities for legal 27,534 43,256 matters Revolving credit facility 180,000 — Current portion of 23,933 6,761 long-term debt, net Current portion of operating lease 14,417 8,668 liabilities Current portion of operating lease 3,398 2,705 liabilities - related party Current portion of financing lease 3,811 3,442 liabilities Related party payables - 18,913 55,485 short term Contingent consideration - related party 59,000 — - short term Total current liabilities 1,119,837 881,633 Long-term debt, net 2,915,501 2,565,115 Operating lease liabilities 59,612 33,233 Operating lease liabilities - related 16,635 14,195 party Financing lease liabilities 65,588 54,927 Related party payables - 15,878 19,132 long term Liabilities for legal matters - long 71,663 71,819 term Contingent consideration - related party 324,000 — - long term Other long-term liabilities 37,797 32,263 Total long-term liabilities 3,506,674 2,790,684 Redeemable non-controlling 109,453 77,292 interests Total stockholders’ equity 531,257 -71,329 (deficiency) Total liabilities and stockholders’ $ 5,267,221 $ 3,678,280 equity (deficiency)
Cash flows from Nine Months Ended operating September 30, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 159,920 $ 78,360 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 144,250 174,345 amortization Unrealized foreign 13,571 -8,606 currency loss (gain) Amortization of debt issuance costs and 12,141 18,716 discount Reclassification of 8,730 -1,713 cash flow hedge Loss on refinancing 9,270 31,365 Intangible asset 975 22,784 impairment charges Research and development 13,832 — equipment impairment charges Non-cash property 5,035 — losses Change in fair value of contingent -6,000 — consideration Stock-based 29,723 23,751 compensation Inventory provision 64,981 59,326 Other operating charges and credits, 4,689 3,575 net Changes in assets and liabilities: Trade accounts -122,423 -110,228 receivable, net Inventories -158,346 -66,846 Prepaid expenses, other current assets -113,073 -20,173 and other assets Related party 203 -830 receivables Accounts payable, accrued expenses and 17,590 2,744 other liabilities Related party -34,756 3,107 payables Net cash provided by operating 50,312 209,677 activities Cash flows from investing activities: Acquisition of Kashiv, net of cash and -421,047 — restricted cash acquired Purchases of property, plant and -70,659 -48,290 equipment Acquisition of -96,603 -12,514 intangible assets Deposits for future acquisition of -28,376 -7,384 property, plant and equipment Proceeds from sale of property, plant — 1,379 and equipment Net cash used in -616,685 -66,809 investing activities Cash flows from financing activities: Payments of principal on debt, revolving -293,172 -2,805,384 credit facilities, financing leases and other Proceeds from 529,853 2,694,750 issuance of debt Payments of deferred financing and -7,549 -74,973 refinancing costs Borrowings on revolving credit 280,000 218,000 facilities Proceeds from exercise of stock 516 1,407 options Employee payroll tax withholding on restricted stock -44,696 -21,957 unit and performance stock unit vesting Tax and other distributions to -29,571 -38,825 non-controlling interests Proceeds from 510 5,572 alliance party Acquisition of non-controlling -400 — interest Net cash provided by (used in) financing 435,491 -21,410 activities Effect of foreign exchange rate on -1,804 -1,471 cash Net decrease in cash, cash -132,686 119,987 equivalents, and restricted cash Cash, cash equivalents, and restricted 312,939 118,420 cash - beginning of period Cash, cash equivalents, and $ 180,253 $ 238,407 restricted cash - end of period Cash and cash equivalents - end of $ 157,399 $ 201,249 period Restricted cash - 14,174 34,727 end of period Long-term restricted cash included in 8,680 2,431 other assets - end of period Cash, cash equivalents, and $ 180,253 $ 238,407 restricted cash - end of period
Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share
(1) Acquisition, site closure, and idle facility expenses for the three and nine months ended September 30, 2026 primarily included acquisition costs associated with the acquisition of Kashiv and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three and nine months ended September 30, 2025 and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties.
(2) Loss on refinancing for the three and nine months ended September 30, 2026 was primarily comprised of debt issuance costs and the write-off of unamortized debt issuance costs. In February 2026, the Company entered into a repricing amendment for the Company’s Term Loan Due 2032 (the “February 2026 Repricing Amendment”), which reduced the applicable interest rate margins on such term loan. In August 2026, the Company entered into another repricing amendment for the Company’s Term Loan Due 2032 (the “August 2026 Repricing Amendment”), which further reduced the applicable interest rate margins on such term loan. Also in August 2026, the Company borrowed an additional $350.0 million under Amendment No. 4 to the Company’s Term Loan Credit Agreement (the “Incremental Term Loans”) to fund a portion of the cash consideration for the Kashiv Acquisition. The loss for the three months ended September 30, 2026 primarily reflects costs associated with the August 2026 Repricing Amendment and the Incremental Term Loans, while the loss for the nine months ended September 30, 2026 primarily reflects costs associated with the February 2026 Repricing Amendment, the August 2026 Repricing Amendment and the Incremental Term Loans. For 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Not e 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2025.
(3) For the three months ended September 30, 2026, charges related to legal matters, net were $7.5 million, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters. For the nine months ended September 30, 2026, charges related to legal matters, net were $16.3 million , primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, (iii) a charge related to government investigations of $8.0 million, and (iv) immaterial net charges related to several matters. For the three and nine months ended September 30, 2026, charges related to legal matters, including interest, net also included interest expense associated with the Nationwide Opioids Settlement Agreement. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
(4) For the three and nine months ended September 30, 2026, impairment charges related to certain equipment used in research and development activities as a result of a change in the expected future utilization of the assets as well as an immaterial intangible asset impairment. For 2025, asset impairment charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application.
(5) During the three and nine months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.
(7) For the year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain.
(8) Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information about the Company’s debt. On August 10, 2026, the Company borrowed an additional $350.0 million under its Term Loan Due 2032, with substantially the same terms as the existing term loans, primarily to finance a portion of the cash consideration for the Kashiv Acquisition. Additionally, in connection with the Kashiv Acquisition, the Company assumed the Kashiv Rupee Term Loan Facility. The Company repaid the facility in full and terminated it on October 1, 2026.
(9) Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.
(10) Gross leverage was calculated by dividing gross debt as of September 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended September 30, 2026 and year ended December 31, 2025, respectively.
(11) Net leverage was calculated by dividing net debt as of September 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended September 30, 2026 and year ended December 31, 2025, respectively.
(12) The non-GAAP effective tax rates for the three and nine months ended September 30, 2026 were 24.0% and 24.5%, respectively. The non-GAAP effective tax rates for the three and nine months ended September 30, 2025 were 23.7% and 24.7%, respectively.
(13) Weighted-average diluted shares outstanding for the three and nine months ended September 30, 2026 and 2025 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities). 11
(1) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.1 million and $0.9 million), amortization expense ($36.0 million and $36.9 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $22.8 million).
(2) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($8.6 million and $6.5 million), amortization expense ($2.6 million and $2.7 million), site closure costs ($0.4 million and $0.6 million), and other ($1.4 million and $1.3 million).
(3) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.9 million and $0.7 million), asset impairment charges ($13.8 million and none), and site closure costs (none and $1.8 million).
(4) Acquisition and integration costs for the three months ended September 30, 2026 were primarily related to professional services fees (e.g., investment banking, legal, due diligence, financial advisory, accounting, and consulting) associated with the acquisition and integration of Kashiv.
(5) During the three months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $7.5 million for the three months ended September 30, 2026, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters. 12
(1) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($3.1 million and $2.8 million), amortization expense ($95.6 million and $122.5 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $22.9 million).
(2) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($24.2 million and $18.4 million), amortization expense ($7.9 million and $8.1 million), site closure costs ($1.4 million and $1.6 million), and other ($4.6 million and $4.0 million).
(3) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.5 million and $2.4 million), asset impairment charges ($13.8 million and none), and site closure costs (none and $3.2 million).
(4) Acquisition and integration costs for the nine months ended September 30, 2026 were primarily related to professional services fees (e.g., investment banking, legal, due diligence, financial advisory, accounting, and consulting) associated with the acquisition and integration of Kashiv.
(5) During the nine months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $16.3 million for the nine months ended September 30, 2026, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, (iii) a charge related to government investigations of $8.0 million, and (iv) immaterial net charges related to several matters. 13
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.1 million in each period), amortization expense ($17.0 million and $10.4 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $0.6 million).
(3) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.4 million and $1.8 million) and site closure costs ($0.4 million and $0.5 million).
(4) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.8 million and $0.7 million) and asset impairment charges ($13.8 million and none).
(5) For the three months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $7.5 million for the three months ended September 30, 2026, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters. 14
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($3.1 million and $2.9 million), amortization expense ($39.1 million and $30.5 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $0.7 million).
(3) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($6.8 million and $4.7 million) and site closure costs ($1.4 million and $1.6 million).
(4) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.2 million and $2.1 million) and asset impairment charges ($13.8 million and none).
(5) For the nine months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $16.3 million for the nine months ended September 30, 2026, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, (iii) a charge related to government investigations of $8.0 million, and (iv) immaterial net charges related to several matters. 15
(1) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of amortization expense ($18.9 million and $26.5 million) and asset impairment charges (none and $22.1 million).
(2) Adjustments for the three months ended September 30, 2026 and 2025 were comprised of stock-based compensation expense.
(3) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.1 million in each period) and site closure costs (none and $1.7 million). 16
(1) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of amortization expense ($56.4 million and $92.0 million) and asset impairment charges (none and $22.1 million).
(2) Adjustments for the nine months ended September 30, 2026 and 2025 were comprised of stock-based compensation expense.
(3) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.4 million and $0.3 million) and site closure costs (none and $3.1 million). 17
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the three months ended September 30, 2026 and 2025 were comprised of amortization expense. 18
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the nine months ended September 30, 2026 and 2025 were comprised of amortization expense. 19
Full text with the tables
Exhibit 99.1
AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted
Loss per Share of $(0.06) –
– Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 –
– Updating 2026 Full Year Guidance –
BRIDGEWATER, NJ, November 3, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)
(“Amneal” or the “Company”) today announced its results for the third quarter
ended September 30, 2026.
“Amneal delivered another quarter of strong, broad-based performance, enabling
us to increase our 2026 guidance once more. As we prepare to enter 2027, our
financial performance is accelerating driven by a number of key catalysts and
new launches, including Women’s Health patches, biosimilars, injectables such as
lanreotide, CREXONT ® , and BREKIYA ® autoinjector. The Kashiv integration is
proceeding well, and we are excited about the long-term growth potential in
biosimilars. With the breadth and depth of opportunities across our portfolio,
we remain highly confident in Amneal’s robust growth outlook,” said Chirag and
Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.
Third Quarter 2026 Results
Net revenue in the third quarter of 2026 was $863 million, an increase of 10%
compared to $785 million in the third quarter of 2025. Affordable Medicines net
revenue increased 19%, driven by biosimilars, women’s health patches, and new
launches. Specialty net revenue increased 20%, driven by key branded products,
including CREXONT ® , BREKIYA ® autoinjector, and UNITHROID ® . AvKARE net
revenue decreased 17%, as expected, due to a non-recurring cardiovascular
product launch in the prior year.
Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in the
third quarter of 2026 compared to net income of $2 million in the third quarter
of 2025 as higher revenue and gross profit were more than offset by non-
recurring acquisition and integration costs, and higher tax provision.
Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of
30% compared to the third quarter of 2025, reflecting higher revenue, higher
gross profit, and lower operating expenses.
Diluted loss per share in the third quarter of 2026 was $(0.06) compared to
diluted income per share of $0.01 for the third quarter of 2025, due to the
aforementioned factors and higher share count as a result of the Kashiv
acquisition. Adjusted diluted earnings per share in the third quarter of 2026
was $0.26, an increase of 53% compared to $0.17 for the third quarter of 2025.
The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please
refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to
non-GAAP reconciliation tables for more information.
1
Updating 2026 Full Year Guidance
We are increasing full year 2026 guidance for net revenue, adjusted EBITDA, and
adjusted diluted EPS. The Company is also updating operating cash flow guidance,
reflecting working capital, including higher inventory levels in key growth
areas.
Updated Guidance Prior Guidance
Net revenue $3.15 billion - $3.25 $3.10 billion - $3.20
billion billion
Adjusted EBITDA(1) $800 million - $815 $750 million - $780
million million
Adjusted diluted $1.04 - $1.08 $0.96 - $1.06
EPS(2)
Operating cash flow(3) $325 million - $375 $350 million - $400
million million
Operating cash flow, $350 million - $400 $375 million - $425
excluding discrete million million
items(4)
Capital ~$150 million ~$150 million
expenditures(5)
(1) Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial
Measures” below.
(2) Accounts for non-controlling interest in AvKARE. Assumes approximately 340
million weighted-average diluted shares outstanding for the year ending December
31, 2026.
(3) Represents cash provided by operating activities.
(4) Excludes discrete items such as opioid settlement costs of approximately $36
million and Kashiv acquisition and integration costs of approximately $40
million.
(5) Reflects estimated capital expenditures and deposits for future acquisition
of property, plant, and equipment.
Amneal’s 2026 estimates are based on management’s current expectations,
including with respect to prescription trends, pricing levels, the timing of
future product launches, the costs incurred and benefits realized of
restructuring activities, and our long-term strategy. The Company’s financial
statements are prepared in accordance with accounting principles generally
accepted in the United States of America (“GAAP”). The Company cannot provide a
reconciliation between non-GAAP projections and the most directly comparable
measures in accordance with GAAP without unreasonable efforts because it is
unable to predict with reasonable certainty the ultimate outcome of certain
significant items required for the reconciliation. The items include, but are
not limited to, acquisition-related expenses, restructuring expenses and
benefits, asset impairments, legal settlements, and other gains and losses.
These items are uncertain, depend on various factors, and could have a material
impact on GAAP reported results.
Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time
today, November 3, 2026, to discuss its results. The live webcast and
presentation will be accessible through the Investor Relations section of the
Company’s website at https://investors.amneal.com. To access the call through a
conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 304152835.
A replay of the conference call will be posted shortly after the call. For a
list of toll-free international numbers, visit this website:
https://help.events.q4inc.com/eahc/international-dial-in-numbers.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New
Jersey, is a diversified, global biopharmaceutical leader focused on expanding
access to affordable and innovative medicines. Amneal was founded in 2002 by
brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that
innovation only matters if it’s accessible. Today, Amneal has a diverse and
growing portfolio of approximately 300 complex generic, specialty and biosimilar
medicines, delivering more than 160 million prescriptions annually, primarily in
the United States. Our Affordable Medicines segment spans retail generics,
injectables, and biosimilars. Our Specialty segment provides branded treatments
in neurology, including Parkinson’s disease and migraine, and endocrinology. Our
AvKARE segment distributes pharmaceuticals and medical products to U.S. federal,
retail, and institutional customers. For additional information, please visit
amneal.com and follow us on LinkedIn.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical
facts, may be forward-looking statements (as defined in the U.S. Private
Securities Litigation Reform Act of 1995). Such forward-looking statements
include statements regarding management’s intentions, plans, beliefs,
expectations, financial results, or forecasts for the future, including among
other things: discussions of future operations; expected or estimated operating
results and financial performance; statements regarding product launches;
statements regarding our potential growth and other non-historical statements.
Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and
similar words, or the negatives thereof, are intended to identify estimates and
forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These
forward-looking statements are based on current expectations of future events,
including with respect to future market conditions, company performance and
financial results, operational investments, business prospects, new strategies
and growth initiatives, the competitive environment, and other
2
events. If the underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially from the
expectations and projections of the Company.
Such risks and uncertainties include, but are not limited to: risks related to
integrating our acquisition (the “Kashiv Acquisition”) of Kashiv BioSciences,
LLC (“Kashiv”) and realizing the anticipated benefits of the acquisition; our
ability to successfully develop, license, acquire and commercialize new products
on a timely basis; the competition we face in the pharmaceutical industry from
brand and generic drug product companies, and the impact of that competition on
our ability to set prices; our ability to obtain exclusive marketing rights for
our products; the impact of illegal distribution and sale by third parties of
counterfeit versions of our products or stolen products; the impact of negative
market perceptions of us and the safety and quality of our products; our
revenues are derived from the sales of a limited number of products, a
substantial portion of which are through a limited number of customers; the
continuing trend of consolidation of certain customer groups; the impact of
supply chain disruption; the imposition of tariffs may adversely affect our
business, results of operations and financial condition; a U.S. government
shutdown could adversely impact our regulatory, operational and financial
performance; legal, regulatory and legislative efforts by our brand competitors
to deter competition from our generic alternatives; our dependence on
information technology systems and infrastructure and the potential for
cybersecurity incidents, and risks associated with artificial intelligence; the
impact of a prolonged business interruption within our supply chain; our ability
to attract, hire and retain highly skilled personnel; risks related to federal
regulation of arrangements between manufacturers of branded and generic
products; our reliance on certain licenses to proprietary technologies from time
to time; the significant amount of resources we expend on research and
development; the risk of claims brought against us by third parties; risks
related to changes in the regulatory environment, including U.S. federal and
state laws related to government contracting, healthcare fraud abuse and health
information privacy and security and changes in such laws; changes to Food and
Drug Administration product approval requirements and review processes; the
impact of healthcare reform and changes in coverage and reimbursement levels and
funding by governmental authorities and other third-party payers; our ability to
identify, make and integrate acquisitions or investments in complementary
businesses and products on advantageous terms; our dependence on third-party
agreements for a portion of our product offerings; our potential expansion into
additional international markets subjecting us to increased regulatory,
economic, social and political uncertainties; the impact of global economic,
political or other catastrophic events; our substantial amount of indebtedness
and our ability to generate sufficient cash to service our indebtedness in the
future, and the impact of interest rate fluctuations on such indebtedness; our
obligations under a tax receivable agreement may be significant; and the high
concentration of ownership of our Class A common stock by the Amneal Group. The
forward-looking statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including under Item 1A,
“Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in
its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to
place undue reliance on any such forward-looking statements, which speak only as
of the date they are made. Forward-looking statements included herein speak only
as of the date hereof and we undertake no obligation to revise or update such
statements to reflect the occurrence of events or circumstances after the date
hereof.
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures, including EBITDA,
adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross
margin, adjusted operating income, net debt, gross leverage, and net leverage,
which are intended as supplemental measures of the Company’s performance that
are not required by or presented in accordance with GAAP.
Management uses these non-GAAP measures internally to evaluate and manage the
Company’s operations and to better understand its business because they
facilitate a comparative assessment of the Company’s operating performance
relative to its performance based on results calculated under GAAP. These non-
GAAP measures also isolate the effects of some items that vary from period to
period without any correlation to core operating performance and eliminate
certain charges that management believes do not reflect the Company’s operations
and underlying operational performance. The compensation committee of the
Company’s board of directors also uses certain of these measures to evaluate
management’s performance and set its compensation. The Company believes that
these non-GAAP measures also provide useful information to investors regarding
certain financial and business trends relating to the Company’s financial
condition and operating results and facilitate an evaluation of the financial
performance of the Company and its operations on a consistent basis. Providing
this information therefore allows investors to make independent assessments of
the Company’s financial performance, results of operations, cash flows, net
leverage and trends while viewing the information through the eyes of
management.
These non-GAAP measures are subject to limitations. The non-GAAP measures
presented in this release may not be comparable to similarly titled measures
used by other companies because other companies may not calculate one or more in
the same manner. Additionally, the non-GAAP performance measures exclude
significant expenses and income that are required by GAAP to be recorded in the
Company’s financial statements; do not reflect changes in, or cash requirements
for, working
3
capital needs; and do not reflect interest expense, or the requirements
necessary to service interest or principal payments on debt. Further, our
historical adjusted results are not intended to project our adjusted results of
operations or financial position for any future period. To compensate for these
limitations, management presents and considers these non-GAAP measures in
conjunction with the Company’s GAAP results; no non-GAAP measure should be
considered in isolation from or as an alternative to any measure determined in
accordance with GAAP. Readers should review the reconciliations included below,
and should not rely on any single financial measure to evaluate the Company’s
business.
A reconciliation of each historical non-GAAP measure to the most directly
comparable GAAP measure is set forth below.
Contact
Anthony DiMeo
VP, Investor Relations
[email protected]
4
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited; in thousands, except per share amounts)
Three Nine
Months Months
Ended Ended
Septemb… Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 862,684 $ 784,513 $ 2,381,… $ 2,204,4…
reven…
Cost
of 528,566 510,539 1,392,… 1,388,3…
goods
sold
Gross 334,118 273,974 988,739 816,118
profit
Selli…
gener… 139,645 137,815 427,227 380,369
and
admin…
Resea…
and 68,374 63,352 145,774 151,356
devel…
Intel…
prope…
legal 2,193 2,437 5,822 6,221
devel…
expen…
Acqui…
and 22,320 — 35,073 —
integ…
costs
Restr…
and 936 143 2,140 1,738
other
charg…
Change
in
fair
value -6,000 — -6,000 —
of
conti…
consi…
Charg…
for
prope…
losses 5,369 — 5,369 —
and
assoc…
expen…
Charg…
(cred…
relat…
to 6,497 — 15,248 -390
legal
matte…
net
Other
opera… -631 -117 -8,870 -5,239
income
Opera… 95,415 70,344 366,956 282,063
income
Other
(expe…
incom…
Inter…
expen… -58,913 -62,814 -167,3… -184,854
net
Forei…
excha…
(loss) -3,174 -3,431 -12,924 9,072
gain,
net
Loss
on -5,760 -31,365 -9,270 -31,365
refin…
(Incr…
decre…
in tax -12,992 20,808 -13,098 5,701
recei…
agree…
liabi…
Other
incom… 481 1,235 1,876 3,357
net
Total
other -80,358 -75,567 -200,7… -198,089
expen…
net
Income
(loss)
before 15,057 -5,223 166,223 83,974
income
taxes
Provi…
for
(bene… 2,751 -23,355 6,303 5,614
from)
income
taxes
Net 12,306 18,132 159,920 78,360
income
Less:
Net
income
attri… -19,762 -15,763 -47,458 -41,379
to
non-c…
inter…
Net
(loss)
income
attri…
to
Amneal
Pharm… -7,456 2,369 112,462 36,981
Inc.
before
accre…
of
redee…
non-c…
inter…
Accre…
of
redee… -14,239 — -14,239 —
non-c…
inter…
Net
(loss)
income
attri… $ -21,695 $ 2,369 $ 98,223 $ 36,981
to
Amneal
Pharm…
Inc.
Net
income
per
share
attri…
to
Amneal
Pharm…
Inc.’s
Class
A
common
stock…
Basic $ -0.06 $ 0.01 $ 0.30 $ 0.12
Dilut… $ -0.06 $ 0.01 $ 0.29 $ 0.11
Weigh…
common
shares
outst…
Basic 335,733 314,168 323,724 312,998
Dilut… 335,733 324,754 335,233 323,704
5
Amneal Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited; in thousands)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash equivalents $ 157,399 $ 282,029
Restricted cash 14,174 28,842
Trade accounts receivable, 1,016,844 895,143
net
Inventories 707,956 606,302
Prepaid expenses and other
current 196,769 98,395
assets
Related party receivables 1,876 470
Total current assets 2,095,018 1,911,181
Property, plant and 572,634 442,950
equipment, net
Goodwill and intangible 2,323,728 1,158,968
assets, net
Operating lease 69,760 38,832
right-of-use assets
Operating lease
right-of-use assets - 20,019 15,216
related party
Financing lease 63,255 53,328
right-of-use assets
Other assets 122,807 57,805
Total assets $ 5,267,221 $ 3,678,280
Liabilities and
Stockholders’ Equity
(Deficiency)
Current liabilities:
Accounts payable and $ 788,831 $ 761,316
accrued expenses
Current portion of
liabilities for legal 27,534 43,256
matters
Revolving credit facility 180,000 —
Current portion of 23,933 6,761
long-term debt, net
Current portion of
operating lease 14,417 8,668
liabilities
Current portion of
operating lease 3,398 2,705
liabilities - related party
Current portion of
financing lease 3,811 3,442
liabilities
Related party payables - 18,913 55,485
short term
Contingent consideration -
related party 59,000 —
- short term
Total current liabilities 1,119,837 881,633
Long-term debt, net 2,915,501 2,565,115
Operating lease liabilities 59,612 33,233
Operating lease liabilities
- related 16,635 14,195
party
Financing lease liabilities 65,588 54,927
Related party payables - 15,878 19,132
long term
Liabilities for legal
matters - long 71,663 71,819
term
Contingent consideration -
related party 324,000 —
- long term
Other long-term liabilities 37,797 32,263
Total long-term liabilities 3,506,674 2,790,684
Redeemable non-controlling 109,453 77,292
interests
Total stockholders’ equity 531,257 -71,329
(deficiency)
Total liabilities and
stockholders’ $ 5,267,221 $ 3,678,280
equity (deficiency)
6
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(unaudited; in thousands)
Cash flows from Nine Months Ended
operating September 30,
activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 159,920 $ 78,360
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 144,250 174,345
amortization
Unrealized foreign 13,571 -8,606
currency loss (gain)
Amortization of debt
issuance costs and 12,141 18,716
discount
Reclassification of 8,730 -1,713
cash flow hedge
Loss on refinancing 9,270 31,365
Intangible asset 975 22,784
impairment charges
Research and
development 13,832 —
equipment
impairment charges
Non-cash property 5,035 —
losses
Change in fair value
of contingent -6,000 —
consideration
Stock-based 29,723 23,751
compensation
Inventory provision 64,981 59,326
Other operating
charges and credits, 4,689 3,575
net
Changes in assets
and liabilities:
Trade accounts -122,423 -110,228
receivable, net
Inventories -158,346 -66,846
Prepaid expenses,
other current assets -113,073 -20,173
and other assets
Related party 203 -830
receivables
Accounts payable,
accrued expenses and 17,590 2,744
other liabilities
Related party -34,756 3,107
payables
Net cash provided by
operating 50,312 209,677
activities
Cash flows from
investing
activities:
Acquisition of
Kashiv, net of cash
and -421,047 —
restricted cash
acquired
Purchases of
property, plant and -70,659 -48,290
equipment
Acquisition of -96,603 -12,514
intangible assets
Deposits for future
acquisition of -28,376 -7,384
property, plant and
equipment
Proceeds from sale
of property, plant — 1,379
and equipment
Net cash used in -616,685 -66,809
investing activities
Cash flows from
financing
activities:
Payments of
principal on debt,
revolving -293,172 -2,805,384
credit facilities,
financing leases and
other
Proceeds from 529,853 2,694,750
issuance of debt
Payments of deferred
financing and -7,549 -74,973
refinancing costs
Borrowings on
revolving credit 280,000 218,000
facilities
Proceeds from
exercise of stock 516 1,407
options
Employee payroll tax
withholding on
restricted stock -44,696 -21,957
unit and performance
stock unit vesting
Tax and other
distributions to -29,571 -38,825
non-controlling
interests
Proceeds from 510 5,572
alliance party
Acquisition of
non-controlling -400 —
interest
Net cash provided by
(used in) financing 435,491 -21,410
activities
Effect of foreign
exchange rate on -1,804 -1,471
cash
Net decrease in
cash, cash -132,686 119,987
equivalents,
and restricted cash
Cash, cash
equivalents, and
restricted 312,939 118,420
cash - beginning of
period
Cash, cash
equivalents, and $ 180,253 $ 238,407
restricted
cash - end of period
Cash and cash
equivalents - end of $ 157,399 $ 201,249
period
Restricted cash - 14,174 34,727
end of period
Long-term restricted
cash included in 8,680 2,431
other assets - end
of period
Cash, cash
equivalents, and $ 180,253 $ 238,407
restricted
cash - end of period
7
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, in thousands)
Reconciliation of Net Income to EBITDA and Adjusted EBITDA
Thr… Nine
Mon… Mon… Year
End… End… End…
Sep… Sep… Dec…
2026 30, 2025 2026 30, 2025 2025 31,
──────────────────────────────────────────────────────────────────────────────
Net $ 12,… $ 18,1… $ 159… $ 78,3… $ 127…
inc…
Adj…
to
add:
Int…
exp… 58,… 62,8… 167… 184,… 241…
net
Pro…
for
(be… 2,7… -23,… 6,3… 5,614 11,…
fro…
inc…
tax…
Dep…
and 53,… 54,0… 144… 174,… 223…
amo…
EBI… $ 127… $ 111,… $ 477… $ 443,… $ 603…
(No…
Adj…
to
add
(de…
Sto…
com… 10,… 8,219 29,… 23,6… 31,…
exp…
Acq…
site
clo…
and 22,… 2,318 36,… 4,762 5,3…
idle
fac…
exp…
Res…
and 890 143 1,3… 1,738 4,2…
oth…
cha…
Loss
on 5,7… 31,3… 9,2… 31,3… 31,…
ref…
Amo…
of
acq… 946 — 946 — —
inv…
ste…
Cha…
(cr…
rel…
to 7,5… — 16,… -390 -390
leg…
mat…
net…
Ass…
imp… 14,… 22,7… 14,… 22,8… 23,…
cha…
For…
exc… 3,1… 3,431 12,… -9,0… -7,…
loss
(ga…
Cha…
in
fair
val… -6,… — -6,… — —
of
con…
con…
Cha…
for
pro…
los… 5,3… — 5,3… — —
and
ass…
exp…
Inc…
(de…
in
tax 12,… -20,… 13,… -5,7… 6,5…
rec…
agr…
lia…
Oth… 1,1… 459 3,4… 829 -9,…
Adj…
EBI… $ 207… $ 159,… $ 615… $ 513,… $ 688…
(No…
8
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, $ in thousands)
Calculation of Net Debt and Net Leverage
September December
30, 2026 31, 2025
──────────────────────────────────────────────────────────────────────────────
Term Loan $ 2,434,263 $ 2,094,750
Due 2032
Senior
Notes Due 600,000 600,000
2032
2025
Revolving 180,000 —
Credit
Facility
Kashiv
Rupee Term 16,484 —
Loan
Facility
Gross $ 3,230,747 $ 2,694,750
debt(8)
Less: Cash
and cash 157,399 282,029
equivalen…
Net debt $ 3,073,348 $ 2,412,721
(Non-GAAP…
Adjusted Adjusted
EBITDA EBITDA
(Non-GAAP) (Non-GAAP)
Year ended
December $ 688,415 $ 688,415
31, 2025
Less:
Nine
months 513,213
ended
September
30, 2025
Add:
Nine
months 615,489
ended
September
30, 2026
Last
twelve
months
ended $ 790,691
September
30,
2026
Last Twelve
Months Year Ended
Ended December
September 31, 2025
30, 2026
Gross
leverage 4.1x 3.9x
(Non-GAAP…
Net
leverage 3.9x 3.5x
(Non-GAAP…
9
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited; in thousands, except per share amounts)
Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted
Diluted Earnings Per Share
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 12,306 $ 18,132 $ 159,920 $ 78,360
income
Adjust…
to add
(deduc…
Non-ca… 7,098 9,163 20,779 16,908
intere…
GAAP
provis…
for
(benef… 2,751 -23,355 6,303 5,614
from)
income
taxes
Amorti… 37,671 38,647 100,696 127,741
Stock-…
compen… 10,515 8,219 29,723 23,621
expense
Acquis…
site
closur…
and 22,745 2,284 36,503 4,700
idle
facili…
expens…
Restru…
and 890 143 1,389 1,731
other
charges
Loss on 5,760 31,365 9,270 31,365
refina…
Amorti…
of
acquir… 946 — 946 —
invent…
step-up
Charges
(credi…
related
to
legal 8,585 — 19,152 -390
matter…
includ…
intere…
net(3)
Asset
impair… 14,809 22,784 14,809 22,888
charge…
Change
in fair
value -6,000 — -6,000 —
of
contin…
consid…
Charges
for
proper…
losses 5,369 — 5,369 —
and
associ…
expens…
Increa…
(decre…
in tax 12,992 -20,808 13,098 -5,701
receiv…
agreem…
liabil…
Other 1,100 459 3,417 839
Provis…
for -28,270 -16,868 -90,030 -65,722
income
taxes(…
Net
income
attrib… -19,762 -15,763 -47,458 -41,379
to
non-co…
intere…
Adjust…
net $ 89,505 $ 54,402 $ 277,886 $ 200,575
income
(Non-G…
Weight…
diluted 348,448 324,754 335,233 323,704
shares
outsta…
Diluted
(loss)
earnin… $ -0.06 $ 0.01 $ 0.29 $ 0.11
per
share
(GAAP)
Adjust…
diluted
earnin… $ 0.26 $ 0.17 $ 0.83 $ 0.62
per
share
(Non-G…
10
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited)
Explanations for Non-GAAP Reconciliations
(1) Acquisition, site closure, and idle facility expenses for the three and nine
months ended September 30, 2026 primarily included acquisition costs associated
with the acquisition of Kashiv and rent for vacated properties. Acquisition,
site closure, and idle facility expenses for the three and nine months ended
September 30, 2025 and year ended December 31, 2025 primarily included costs
related to a planned facility closure and rent for vacated properties.
(2) Loss on refinancing for the three and nine months ended September 30, 2026
was primarily comprised of debt issuance costs and the write-off of unamortized
debt issuance costs. In February 2026, the Company entered into a repricing
amendment for the Company’s Term Loan Due 2032 (the “February 2026 Repricing
Amendment”), which reduced the applicable interest rate margins on such term
loan. In August 2026, the Company entered into another repricing amendment for
the Company’s Term Loan Due 2032 (the “August 2026 Repricing Amendment”), which
further reduced the applicable interest rate margins on such term loan. Also in
August 2026, the Company borrowed an additional $350.0 million under Amendment
No. 4 to the Company’s Term Loan Credit Agreement (the “Incremental Term Loans”)
to fund a portion of the cash consideration for the Kashiv Acquisition. The loss
for the three months ended September 30, 2026 primarily reflects costs
associated with the August 2026 Repricing Amendment and the Incremental Term
Loans, while the loss for the nine months ended September 30, 2026 primarily
reflects costs associated with the February 2026 Repricing Amendment, the August
2026 Repricing Amendment and the Incremental Term Loans. For 2025, loss on
refinancing was primarily comprised of debt issuance costs associated with the
portion of the Term Loan Due 2028 that was modified as part of the Company’s
debt refinancing on August 1, 2025. Refer to Not e 14. Debt in the Company’s
2025 Annual Report on Form 10-K for information about the Company’s debt as of
December 31, 2025.
(3) For the three months ended September 30, 2026, charges related to legal
matters, net were $7.5 million, primarily consisting of a charge related to
government investigations of $8.0 million, partially offset by immaterial net
credits related to several matters. For the nine months ended September 30,
2026, charges related to legal matters, net were $16.3 million , primarily
consisting of (i) a $21.2 million charge associated with certain states electing
a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement
Agreement, partially offset by a $20.8 million discount recorded on the expected
settlement payments as of the agreement’s effective date, (ii) net charges
associated with antitrust class action litigation of $7.5 million, (iii) a
charge related to government investigations of $8.0 million, and (iv) immaterial
net charges related to several matters. For the three and nine months ended
September 30, 2026, charges related to legal matters, including interest, net
also included interest expense associated with the Nationwide Opioids Settlement
Agreement. For additional information regarding the Nationwide Opioids
Settlement Agreement and antitrust class action litigation, refer to Note 16.
Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2026.
(4) For the three and nine months ended September 30, 2026, impairment charges
related to certain equipment used in research and development activities as a
result of a change in the expected future utilization of the assets as well as
an immaterial intangible asset impairment. For 2025, asset impairment charges
primarily related to a Specialty segment product right for which the Company
significantly reduced the cash flow forecast after receipt of a complete
response letter dated July 22, 2025 from the U.S. Food and Drug Administration
regarding a supplemental new drug application.
(5) During the three and nine months ended September 30, 2026, the Company
recognized a $6.0 million gain related to the remeasurement of contingent
consideration associated with the Kashiv Acquisition. The gain reflects the
periodic remeasurement of the contingent consideration liability driven
primarily by increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.
(7) For the year ended December 31, 2025, the caption “other” primarily reflects
a non-recurring, non-operating, non-cash gain.
(8) Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for
additional information about the Company’s debt. On August 10, 2026, the Company
borrowed an additional $350.0 million under its Term Loan Due 2032, with
substantially the same terms as the existing term loans, primarily to finance a
portion of the cash consideration for the Kashiv Acquisition. Additionally, in
connection with the Kashiv Acquisition, the Company assumed the Kashiv Rupee
Term Loan Facility. The Company repaid the facility in full and terminated it on
October 1, 2026.
(9) Net debt was calculated as the total outstanding principal on the Company’s
debt less cash and cash equivalents.
(10) Gross leverage was calculated by dividing gross debt as of September 30,
2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended
September 30, 2026 and year ended December 31, 2025, respectively.
(11) Net leverage was calculated by dividing net debt as of September 30, 2026
and December 31, 2025 by adjusted EBITDA for the last twelve months ended
September 30, 2026 and year ended December 31, 2025, respectively.
(12) The non-GAAP effective tax rates for the three and nine months ended
September 30, 2026 were 24.0% and 24.5%, respectively. The non-GAAP effective
tax rates for the three and nine months ended September 30, 2025 were 23.7% and
24.7%, respectively.
(13) Weighted-average diluted shares outstanding for the three and nine months
ended September 30, 2026 and 2025 consisted of fully diluted Class A common
stock (inclusive of the effect of dilutive securities).
11
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, $ in thousands)
Reconciliation of Consolidated GAAP to Non-GAAP Operating Results
T… T…
M… M…
E… E…
S… S…
3… 3…
2… 2…
──────────────────────────────────────────────────────────────────────────────
As A… N… As Ad… No…
R… Re…
… $ 8… $ — $ 8… $ 7… $ — $ 7…
…
…
… 5… -… 4… 5… -… 4…
…
…
… 3… 3… 3… 2… 6… 3…
…
…
… 3… % 4… % 3… % 4… %
%
…
… 1… -… 1… 1… -… 1…
…
…
…
… 6… -… 5… 6… -… 6…
…
…
…
… 2… — 2… 2… — 2…
…
…
…
… 2… -… — — — —
…
…
…
… 9… -… 46 1… -… —
…
…
…
…
…
… -… 6… — — — —
…
…
…
…
…
…
… 5… -… — — — —
…
…
…
…
…
…
… 6… -… -… — — —
…
…
…
…
… -… — -… -… — -…
…
… $ 9… $ 9… $ 1… $ 7… $ 7… $ 1…
…
(1) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($1.1 million
and $0.9 million), amortization expense ($36.0 million and $36.9 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $22.8 million).
(2) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($8.6 million
and $6.5 million), amortization expense ($2.6 million and $2.7 million), site
closure costs ($0.4 million and $0.6 million), and other ($1.4 million and $1.3
million).
(3) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.9 million
and $0.7 million), asset impairment charges ($13.8 million and none), and site
closure costs (none and $1.8 million).
(4) Acquisition and integration costs for the three months ended September 30,
2026 were primarily related to professional services fees (e.g., investment
banking, legal, due diligence, financial advisory, accounting, and consulting)
associated with the acquisition and integration of Kashiv.
(5) During the three months ended September 30, 2026, the Company recognized a
$6.0 million gain related to the remeasurement of contingent consideration
associated with the Kashiv Acquisition. The gain reflects the periodic
remeasurement of the contingent consideration liability driven primarily by
increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $7.5
million for the three months ended September 30, 2026, primarily consisting of a
charge related to government investigations of $8.0 million, partially offset by
immaterial net credits related to several matters.
12
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, $ in thousands)
Reconciliation of Consolidated GAAP to Non-GAAP Operating Results
N… Ni…
M… Mo…
E… En…
S… Se…
3… 30,
2… 20…
──────────────────────────────────────────────────────────────────────────────
As A… N… As A… N…
R… R…
… $ 2… $ — $ 2… $ 2,… $ — $ 2,…
…
…
… 1… -… 1… 1,… -1… 1,…
…
…
… 9… 1… 1… 81… 14… 96…
…
…
… 4… % 4… % 37… % 43… %
%
…
… 4… -… 3… 38… -3… 34…
…
…
…
… 1… -… 1… 15… -5… 14…
…
…
…
… 5… — 5… 6,… — 6,…
…
…
…
… 3… -… — — — —
…
…
…
… 2… -… 7… 1,… -1… —
…
…
…
…
…
… -… 6… — — — —
…
…
…
…
…
…
… 5… -… — — — —
…
…
…
…
…
…
… 1… -… -… -3… 390 —
…
…
…
…
… -… — -… -5… — -5…
…
… $ 3… $ 2… $ 5… $ 28… $ 18… $ 46…
…
(1) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($3.1 million
and $2.8 million), amortization expense ($95.6 million and $122.5 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $22.9 million).
(2) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($24.2 million
and $18.4 million), amortization expense ($7.9 million and $8.1 million), site
closure costs ($1.4 million and $1.6 million), and other ($4.6 million and $4.0
million).
(3) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($2.5 million
and $2.4 million), asset impairment charges ($13.8 million and none), and site
closure costs (none and $3.2 million).
(4) Acquisition and integration costs for the nine months ended September 30,
2026 were primarily related to professional services fees (e.g., investment
banking, legal, due diligence, financial advisory, accounting, and consulting)
associated with the acquisition and integration of Kashiv.
(5) During the nine months ended September 30, 2026, the Company recognized a
$6.0 million gain related to the remeasurement of contingent consideration
associated with the Kashiv Acquisition. The gain reflects the periodic
remeasurement of the contingent consideration liability driven primarily by
increases in the discount rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $16.3
million for the nine months ended September 30, 2026, primarily consisting of
(i) a $21.2 million charge associated with certain states electing a 25% cash
conversion in lieu of product under the Nationwide Opioids Settlement Agreement,
partially offset by a $20.8 million discount recorded on the expected settlement
payments as of the agreement’s effective date, (ii) net charges associated with
antitrust class action litigation of $7.5 million, (iii) a charge related to
government investigations of $8.0 million, and (iv) immaterial net charges
related to several matters.
13
Amneal Pharmaceuticals, Inc.
Affordable Medicines Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(1)
(unaudited; $ in thousands)
T… T…
M… M…
E… E…
S… S…
3… 3…
2… 2…
──────────────────────────────────────────────────────────────────────────────
As A… N… As Ad… No…
R… Re…
… $ 5… $ — $ 5… $ 4… $ — $ 4…
…
…
… 3… -… 3… 2… -… 2…
…
…
… 1… 2… 2… 1… 1… 1…
…
…
… 3… % 3… % 3… % 4… %
%
…
… 3… -… 2… 3… -… 3…
…
…
…
… 6… -… 4… 5… -… 5…
…
…
…
… 2… — 2… 2… — 2…
…
…
…
… 8… -… — 90 -… —
…
…
…
…
…
… -… 6… — — — —
…
…
…
…
…
…
… 5… -… — — — —
…
…
…
…
…
…
… 5… -… -… — — —
…
…
…
…
… -… — -… -… — -…
…
… $ 9… $ 4… $ 1… $ 8… $ 1… $ 1…
…
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($1.1 million
in each period), amortization expense ($17.0 million and $10.4 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $0.6 million).
(3) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($2.4 million
and $1.8 million) and site closure costs ($0.4 million and $0.5 million).
(4) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.8 million
and $0.7 million) and asset impairment charges ($13.8 million and none).
(5) For the three months ended September 30, 2026, the Company recognized a $6.0
million gain related to the remeasurement of contingent consideration associated
with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the
contingent consideration liability driven primarily by increases in the discount
rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $7.5
million for the three months ended September 30, 2026, primarily consisting of a
charge related to government investigations of $8.0 million, partially offset by
immaterial net credits related to several matters.
14
Amneal Pharmaceuticals, Inc.
Affordable Medicines Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(1)
(unaudited; $ in thousands)
N… N…
M… M…
E… E…
S… S…
3… 3…
2… 2…
──────────────────────────────────────────────────────────────────────────────
As A… N… As A… N…
R… R…
… $ 1… $ — $ 1… $ 1… $ — $ 1,…
…
…
… 8… -… 8… 7… -3… 74…
…
…
… 5… 4… 6… 5… 34… 56…
…
…
… 4… % 4… % 4… % 43… %
%
…
… 1… -… 1… 1… -6… 98…
…
…
…
… 1… -… 1… 1… -2… 12…
…
…
…
… 5… — 5… 6… — 6,…
…
…
…
… 8… -… — 7… -7… —
…
…
…
…
…
… -… 6… — — — —
…
…
…
…
…
…
… 5… -… — — — —
…
…
…
…
…
…
… 1… -… -… -… 390 —
…
…
…
…
… -… — -… -… — -5…
…
… $ 3… $ 8… $ 4… $ 2… $ 42… $ 3…
…
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($3.1 million
and $2.9 million), amortization expense ($39.1 million and $30.5 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $0.7 million).
(3) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($6.8 million
and $4.7 million) and site closure costs ($1.4 million and $1.6 million).
(4) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($2.2 million
and $2.1 million) and asset impairment charges ($13.8 million and none).
(5) For the nine months ended September 30, 2026, the Company recognized a $6.0
million gain related to the remeasurement of contingent consideration associated
with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the
contingent consideration liability driven primarily by increases in the discount
rate subsequent to the acquisition date.
(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.
(7) Adjustments to charges (credit) related to legal matters, net were $16.3
million for the nine months ended September 30, 2026, primarily consisting of
(i) a $21.2 million charge associated with certain states electing a 25% cash
conversion in lieu of product under the Nationwide Opioids Settlement Agreement,
partially offset by a $20.8 million discount recorded on the expected settlement
payments as of the agreement’s effective date, (ii) net charges associated with
antitrust class action litigation of $7.5 million, (iii) a charge related to
government investigations of $8.0 million, and (iv) immaterial net charges
related to several matters.
15
Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)
T… T…
M… M…
E… E…
S… S…
3… 3…
2… 2…
──────────────────────────────────────────────────────────────────────────────
As A… N… As Ad… No…
R… Re…
… $ 1… $ — $ 1… $ 1… $ — $ 1…
…
…
… 4… -… 2… 7… -… 2…
…
…
… 1… 1… 1… 5… 4… 1…
…
…
… 6… % 8… % 4… % 7… %
%
…
… 3… -… 3… 3… -… 3…
…
…
…
… 4… -… 4… 8… -… 6…
…
…
…
… 55 — 55 59 — 59
…
…
…
… — — — — — —
…
…
…
…
…
… 35 -… — — — —
…
…
…
…
…
… 1… — 1… — — —
…
…
…
… $ 6… $ 1… $ 8… $ 9… $ 5… $ 6…
…
(1) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of amortization expense ($18.9 million and $26.5
million) and asset impairment charges (none and $22.1 million).
(2) Adjustments for the three months ended September 30, 2026 and 2025 were
comprised of stock-based compensation expense.
(3) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.1 million
in each period) and site closure costs (none and $1.7 million).
16
Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)
N… N…
M… M…
E… E…
S… S…
3… 3…
2… 2…
──────────────────────────────────────────────────────────────────────────────
As A… N… As Ad… No…
R… Re…
… $ 4… $ — $ 4… $ 3… $ — $ 3…
…
…
… 1… -… 8… 1… -… 6…
…
…
… 2… 5… 3… 1… 1… 2…
…
…
… 6… % 8… % 4… % 8… %
%
…
… 1… -… 1… 9… -… 9…
…
…
…
… 1… -… 1… 2… -… 1…
…
…
…
… 1… — 1… 1… — 1…
…
…
…
… 3… -… — 4… -… —
…
…
…
…
…
… 35 -… — — — —
…
…
…
…
…
… 1… — 1… — — —
…
…
…
… $ 1… $ 5… $ 2… $ 6… $ 1… $ 1…
…
(1) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of amortization expense ($56.4 million and $92.0
million) and asset impairment charges (none and $22.1 million).
(2) Adjustments for the nine months ended September 30, 2026 and 2025 were
comprised of stock-based compensation expense.
(3) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.4 million
and $0.3 million) and site closure costs (none and $3.1 million).
17
Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(1)
(unaudited; $ in thousands)
T… Th…
M… Mo…
E… En…
S… Se…
3… 30,
2… 20…
──────────────────────────────────────────────────────────────────────────────
As A… N… As A… N…
R… R…
… $ 1… $ — $ 1… $ 19… $ — $ 19…
…
…
… 1… — 1… 15… — 15…
…
…
… 3… — 3… 42… — 42…
…
…
… 2… % 2… % 21… % 21… %
%
…
… 1… -… 1… 15… -2… 12…
…
…
… $ 1… $ 2… $ 2… $ 27… $ 2,… $ 29…
…
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the three months ended September 30, 2026 and 2025 were
comprised of amortization expense.
18
Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(1)
(unaudited; $ in thousands)
N… Ni…
M… Mo…
E… En…
S… Se…
3… 30,
2… 20…
──────────────────────────────────────────────────────────────────────────────
As A… N… As A… N…
R… R…
… $ 4… $ — $ 4… $ 53… $ — $ 53…
…
…
… 3… — 3… 42… — 42…
…
…
… 1… — 1… 10… — 10…
…
…
… 2… % 2… % 19… % 19… %
%
…
… 5… -… 4… 46… -8… 37…
…
…
… $ 4… $ 7… $ 5… $ 58… $ 8,… $ 66…
…
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.
(2) Adjustments for the nine months ended September 30, 2026 and 2025 were
comprised of amortization expense.
19